Teva MS Drug Patents Invalidated By Fed. Circ.

Law360, New York (July 26, 2013, 7:10 PM EDT) -- The Federal Circuit ruled Friday that several patents covering Teva Pharmaceuticals USA Inc.'s multiple sclerosis drug Copaxone are invalid, reversing a lower court and clearing the way for Mylan Inc. and Sandoz Inc. to launch generic versions.

The appeals court found that five of the nine patents Teva alleged would be infringed by Mylan and Sandoz's planned generics are invalid as indefinite because their claims contain ambiguous language. The court held that the four other patents were not ambiguous and affirmed the district court's June 2012...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.